에서 실시간으로 운영 중이에요! 자세히 알아보기

IQVIA

IQV

시가총액 US$439억

266.90 USD

-4.14

1.53%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

266.90

0.00

0%

1일

-1.53%

5일

2.56%

1개월

-0.71%

3개월

26.8%

6개월

55.22%

연초 이후

18.43%

1년

29.72%

5년

7.42%

10년

254.54%

소개: Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

직원 수: 94,000

건강관리 진단 및 리서치

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 56.8%

중립 35.1%

부정적 8.1%

IQVIA Selects Veeva Clinical Operations Applications

RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.

IQVIA Selects Veeva Clinical Operations Applications

Zacks Investment Research

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes. IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA's proprietary expert content, deep domain knowledge and established regulatory, com.

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Explorer™ to help customers make better-informed commercial decisions. IQVIA Explorer turns complex, one-time analytics projects into an always-on commercial intelligence capability. Users can apply external indicators and ask business questio.

IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions

Zacks Investment Research

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanyin.

IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

Zacks Investment Research

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

Zacks Investment Research

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

IQVIA Announces Pricing of Senior Notes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and e.

IQVIA Announces Pricing of Senior Notes

IQVIA Announces Offering of Senior Notes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and expenses relate.

IQVIA Announces Offering of Senior Notes

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.